Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cytotherapy

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcyt.2013.09.008PMID 24280238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccination Route Matters for Mucosal Tumors

  2013cited by this paper
• Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer

  2013cited by this paper
• IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

  2013cited by this paper
• Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

  2013cited by this paper
• Immune system targeting by biodegradable nanoparticles for cancer vaccines.

  2013cited by this paper
• PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

  2013cited by this paper
• Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

  2013cited by this paper
• Dendritic cells and their role in tumor immunosurveillance

  2013cited by this paper
• Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination

  2013cited by this paper
• Higher numbers of T-bet+ intratumoral lymphoid cells correlate with better survival in gastric cancer

  2013cited by this paper
• Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β.

  2013cited by this paper
• Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors

  2013cited by this paper
• Decisions about dendritic cells: past, present, and future.

  2012cited by this paper
• Distinct APCs Explain the Cytokine Bias of α-Galactosylceramide Variants In Vivo

  2012cited by this paper
• The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming.

  2012cited by this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cited by this paper
• Cellular constituents of immune escape within the tumor microenvironment.

  2012cited by this paper
• Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications

  2012cited by this paper
• Mechanisms of immune evasion by gliomas.

  2012cited by this paper
• Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• Dendritic Cell–Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells

  2012cited by this paper
• The secret ally: immunostimulation by anticancer drugs

  2012cited by this paper
• Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells

  2011cited by this paper
• Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma

  2011cited by this paper
• DNA released from dying host cells mediates aluminum adjuvant activity

  2011cited by this paper
• Trends in vaccine adjuvants

  2011cited by this paper
• Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

  2011cited by this paper
• Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation.

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity.

  2011cited by this paper
• Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

  2011cited by this paper
• A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV).

  2011cited by this paper
• Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

  2010cited by this paper
• Versatile Virus-Like Particle Carrier for Epitope Based Vaccines

  2010cited by this paper
• Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

  2010cited by this paper
• Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Pattern recognition receptors and inflammation.

  2010cited by this paper
• Efficient Eradication of Subcutaneous but Not of Autochthonous Gastric Tumors by Adoptive T Cell Transfer in an SV40 T Antigen Mouse Model

  2010cited by this paper
• Induction of T cell anergy: integration of environmental cues and infectious tolerance.

  2010cited by this paper
• Concomitant Activation and Antigen Uptake via Human Dectin-1 Results in Potent Antigen-Specific CD8+ T Cell Responses

  2010cited by this paper
• Semi Mature Blood Dendritic Cells Exist in Patients with Ductal Pancreatic Adenocarcinoma Owing to Inflammatory Factors Released from the Tumor

  2010cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12.

  2009cited by this paper
• Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells.

  2009cited by this paper
• Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

  2009cited by this paper
• A systematic review of humoral immune responses against tumor antigens

  2009cited by this paper
• Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.

  2008cited by this paper
• Antigen-presentation properties of plasmacytoid dendritic cells.

  2008cited by this paper
• Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

  2008cited by this paper
• CD54 is a surrogate marker of antigen presenting cell activation

  2008cited by this paper
• Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration

  2008cited by this paper
• Spontaneous and treatment-induced cancer rejection in humans.

  2008cited by this paper
• Spontaneous and treatment-induced cancer rejection in humans

  2008cited by this paper
• Molecular and cellular signatures of human vaccine adjuvants

  2008cited by this paper
• The capacity of the TNF family members 4‐1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells

  2008cited by this paper
• Human Langerhans’ cells and dermal‐type dendritic cells generated from CD34 stem cells express different toll‐like receptors and secrete different cytokines in response to toll‐like receptor ligands

  2008cited by this paper
• Immunological decision‐making: how does the immune system decide to mount a helper T‐cell response?

  2008cited by this paper
• Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

  2008cited by this paper
• Bridging the knowledge gaps in vaccine design

  2007cited by this paper
• DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27

  2007cited by this paper
• Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer

  2007cited by this paper
• A subset of dendritic cells induces CD4+ T cells to produce IFN-γ by an IL-12–independent but CD70-dependent mechanism in vivo

  2007cited by this paper
• Duration, combination and timing: the signal integration model of dendritic cell activation.

  2007cited by this paper
• B Subunit of Shiga Toxin-Based Vaccines Synergize with α-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity1

  2007cited by this paper
• Cancer despite immunosurveillance: immunoselection and immunosubversion

  2006cited by this paper
• Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity.

  2006cited by this paper
• Impaired function of circulating dendritic cells in patients with pancreatic cancer.

  2005cited by this paper
• Signal 3 Tolerant CD8 T Cells Degranulate in Response to Antigen but Lack Granzyme B to Mediate Cytolysis1

  2005cited by this paper
• Biodistribution of radiolabelled human dendritic cells injected by various routes

  2005cited by this paper
• Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells.

  2004cited by this paper
• Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells1

  2004cited by this paper
• Human epidermal Langerhans cells differ from monocyte‐derived Langerhans cells in CD80 expression and in secretion of IL‐12 after CD40 cross‐linking

  2004cited by this paper
• The three Es of cancer immunoediting.

  2004cited by this paper
• Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL

  2004cited by this paper
• alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

  2004cited by this paper
• Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

  2003cited by this paper
• Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity.

  2003cited by this paper
• Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.

  2003cited by this paper
• Flexibility of Mouse Classical and Plasmacytoid-derived Dendritic Cells in Directing T Helper Type 1 and 2 Cell Development

  2003cited by this paper
• Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.

  2002cited by this paper
• A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection

  2001cited by this paper
• Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells

  2000cited by this paper
• Development of Th1-Inducing Capacity in Myeloid Dendritic Cells Requires Environmental Instruction1

  2000cited by this paper
• Migration of human dendritic cells after injection in patients with metastatic malignancies.

  1999cited by this paper
• Cytokines induce the development of functionally heterogeneous T helper cell subsets.

  1998cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper

• Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook

  2026cites this paper
• Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM)

  2025cites this paper
• Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer

  2024cites this paper
• Cry1Ac Protoxin Confers Antitumor Adjuvant Effect in a Triple-Negative Breast Cancer Mouse Model by Improving Tumor Immunity

  2022cites this paper
• Framework Nucleic Acid Immune Adjuvant for Transdermal Delivery Based Chemo-immunotherapy for Malignant Melanoma Treatment.

  2022cites this paper
• Cry1Ac Protoxin Confers Antitumor Adjuvant Effect in a Triple-Negative Breast Cancer Mouse Model by Improving Tumor Immunity.

  2022cites this paper
• Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells

  2020cites this paper
• Activation of human vascular endothelium in melanoma metastases induces ICAM‐1 and E‐selectin expression and results in increased infiltration with effector lymphocytes

  2019cites this paper
• Vaccines, Adjuvants, and Delivery Systems

  2019cites this paper
• Stored red blood cells enhance in vivo migration of dendritic cells by promoting reactive oxygen species–induced cytoskeletal rearrangement

  2019cites this paper
• Immune response evoked by tumor-associated NADH oxidase (tNOX) confers potential inhibitory effect on lung carcinoma in a mouse model.

  2019cites this paper
• Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor

  2018cites this paper
• Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model.

  2018cites this paper
• Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis

  2018cites this paper
• Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.

  2018cites this paper
• Vaccinations in Rheumatology

  2018cites this paper
• Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model.

  2017cites this paper
• Modifying Dendritic Cell Activation with Plasmonic Nano Vectors

  2017cites this paper
• Host-Derived Cytokines and Chemokines as Vaccine Adjuvants

  2017cites this paper
• Dendritic Cells as Targets of Vaccines and Adjuvants

  2017cites this paper
• Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

  2017cites this paper
• Mature dendritic cell derived from cryopreserved immature dendritic cell shows impaired homing ability and reduced anti-viral therapeutic effects

  2016cites this paper
• Adjuvants in micro- to nanoscale: current state and future direction.

  2016cites this paper
• Levamisole promotes murine bone marrow derived dendritic cell activation and drives Th1 immune response in vitro and in vivo.

  2016cites this paper
• Therapeutic Cancer Vaccines.

  2016cites this paper
• Therapeutic vaccination strategies to treat nasopharyngeal carcinoma.

  2016cites this paper
• The transduction pattern of IL‐12‐encoding lentiviral vectors shapes the immunological outcome

  2015cites this paper
• Oil‐Based Emulsion Vaccine Adjuvants

  2014cites this paper
• Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?

  2014cites this paper
• Anti-tumor activities of peptides corresponding to conserved complementary determining regions from different immunoglobulins.

  2014cites this paper
• Therapeutic cancer vaccines.

  2010cites this paper